Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Mandy L. Ballinger(Garvan Institute of Medical Research), David M. Thomas(New South Wales Department of Health), Beatrice Seddon(University College London Hospitals NHS Foundation Trust), Paul A. James(The Royal Melbourne Hospital), Ola Myklebost(Oslo University Hospital), Joshua D. Schiffman(Primary Children's Hospital), Rajiv Sarin(Homi Bhabha National Institute), Andrew S. Brohl(Moffitt Cancer Center), Ian Campbell(The University of Sydney), Jin Hee Ahn(Asan Medical Center), Jean‐Yves Blay(Université Claude Bernard Lyon 1), David L. Goode(Peter MacCallum Cancer Centre), Victoria Beshay(Peter MacCallum Cancer Centre), Sung‐Min Ahn(Gachon University), Ian Judson(Erasmus Hospital), Mary‐Anne Young(University of Melbourne), R. Lor Randall(University of California Davis Medical Center), Eva W. Stratford(Oslo University Hospital), Séan O’Donoghue(Commonwealth Scientific and Industrial Research Organisation), Eveline Niedermayr(Peter MacCallum Cancer Centre), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Isabelle Ray‐Coquard(Centre Léon Bérard), Arcadi Cipponi(The Kinghorn Cancer Centre), Ajay Puri(Homi Bhabha National Institute), Gillian S. Dite(University of Melbourne), Jeong Eun Kim(Asan Medical Center), Susanne Lorenz(Oslo University Hospital), Gillian Mitchell(Peter MacCallum Cancer Centre), Sue Shanley(Peter MacCallum Cancer Centre)
Cited by 213
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k